Novanta's Acquisition Costs Climb As Sales Rise 23% And Reported Profit Falls

Adjusted earnings rose to $1.05 per share, while medical sales grew and the segment's gross margin declined.

Share
Novanta's Acquisition Costs Climb As Sales Rise 23% And Reported Profit Falls

Novanta, which makes components for medical, life science and advanced industrial equipment, grew third-quarter sales 23% to $305 million, with acquisitions adding $32.9 million, according to results accompanying Monday's SEC filing. Profit fell to $2 million from $10.7 million a year earlier as acquisition expenses and amortization increased.

The Cost Of Buying Growth

Acquisition-related expenses reached $19.219 million, versus $1.474 million a year earlier. Amortization—the accounting charge for acquired intangible assets—was $21.408 million, up from $11.180 million.

Operating income fell to $13.9 million from $21.8 million. Reported earnings per share dropped to $0.05 from $0.30, while adjusted earnings, which exclude acquisition expenses, amortization and other specified items, rose about 21% to $1.05 from $0.87.

Novanta's adjusted earnings before interest, taxes, depreciation and amortization increased 38.3% to $80.3 million from $58.1 million. Its margin on that measure reached 26.3%, versus 23.4%.

Sales compared with $247.8 million a year earlier. Excluding acquisitions and currency effects, revenue grew 9.9%; exchange-rate changes reduced sales by $0.3 million.

Medical Sales Grow, Margins Narrow

Medical Solutions generated $160 million in sales, versus $123 million a year earlier. Gross profit increased to $64 million from $53 million, but gross margin fell to 39.9% from 43.0%.

Automation Enabling Technologies sales reached $145 million, compared with $125 million. That segment's gross profit rose to $73 million from $59 million, and its gross margin improved to 50.2% from 47.3%.

Novanta sells lasers, precision motors, sensors and robotic tooling through its automation business. Medical Solutions supplies surgical pumps, disposables, imaging systems and operating-room video technology. The company sells worldwide, mainly directly to equipment manufacturers; medical customers represented approximately 53% of 2025 revenue and advanced industrial customers approximately 47%.

The company has expanded through technology purchases, internal investment and consolidation of operations. During the quarter it closed Riverpoint Medical, which Matthijs Glastra, Novanta's chair and chief executive officer, called its largest acquisition. Glastra said Riverpoint was meeting expectations; Novanta identifies integration, achieving anticipated benefits and meeting its borrowing requirements as risks.

More Cash, More Debt

Operating cash flow rose to $39.3 million from $8.5 million a year earlier. For the first nine months, it reached $155.9 million, versus $55.3 million. Novanta paid $1.2 billion for business acquisitions during the quarter and borrowed $626 million under senior credit facilities.

Total debt stood at $829.8 million on October 2, compared with $250.8 million at December 31, 2025. Cash was $149.2 million, versus $380.9 million at that year-end.

Customer bookings increased 29% from a year earlier, bringing the backlog to $543 million. Novanta expects fourth-quarter revenue of $306 million to $312 million, reported growth of more than 18%, and adjusted earnings of $0.91 to $0.96 per share.

For 2026, management expects revenue of $1.135 billion to $1.140 billion and adjusted earnings of $3.66 to $3.71 per share. Glastra said the company remains on track for approximately 7% organic revenue growth, approximately 16% reported growth and approximately $200 million in operating cash flow.

“Looking ahead to 2027, we expect reported revenue growth of more than 15%,” Glastra said.

Novanta is scheduled to discuss the results and provide a business update on Tuesday's conference call.

Sources